文献速递认知障碍与痴呆

血浆p-tau217与阿尔茨海默病各阶段临床恶化的关联

Association of Plasma Phosphorylated Tau 217 With Clinical Deterioration Across Alzheimer Disease Stages.
PubMed 文献 · Neurology · 2025-06-05

本研究基于Sant Pau神经退行性疾病倡议的回顾性纵向队列,纳入731名参与者,按脑脊液p-tau181/Aβ1-42比值分为临床1-6期,随访至多10年。结果显示血浆p-tau217随AD分期显著升高,且基线水平与更快的MMSE下降及痴呆进展独立相关。提示血浆p-tau217可作为监测AD进展的预后标志物。

要点

  • 血浆p-tau217随AD临床分期进展显著升高。
  • 基线血浆p-tau217较高者MMSE下降更快、痴呆进展风险更高。
  • 该关联独立于临床分期,支持其作为预后监测工具。

核心结论

  • 血浆p-tau217与AD患者认知和功能下降显著相关,支持其作为预后标志物用于临床监测AD进展。

研究设计与样本

  • 回顾性纵向队列研究,数据来自Sant Pau神经退行性疾病倡议(2011-2022年),共纳入731名参与者,平均年龄71.5±10.1岁,女性占60%,随访至多10年。

主要发现

  • 血浆p-tau217水平随AD分期进展显著升高,所有组间比较经FDR校正后仍显著(p<0.05)。
  • 纵向分析显示血浆p-tau217显著升高(β=7.7,95%CI 3.0-12.5,p=0.002),脑脊液p-tau181亦显著升高(β=3.2,95%CI 1.4-5.0,p=0.001)。
  • 基线血浆p-tau217与更快的MMSE下降相关(β=-0.08,95%CI -0.11至-0.05,p<0.001)。
  • 基线血浆p-tau217与痴呆进展风险相关(HR=1.03,95%CI 1.01-1.05,p<0.001),独立于临床分期。

临床怎么用

  • 血浆p-tau217或可用于临床实践中监测AD患者的疾病进展和预后评估。

局限性

  • 研究为回顾性设计,结果需在多样化队列中验证,其在早期检测和监测中的效用尚待探索。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Phosphorylated tau at threonine 217 (p-tau217) is a highly sensitive blood-based biomarker for Alzheimer disease (AD) pathology, showing high diagnostic accuracy. However, its prognostic value across different clinical stages of AD remains unclear. The aim of this study was to assess the prognostic utility of plasma p-tau217, measured using a commercially available immunoassay, regarding clinical and functional decline across the clinical stages of AD in a cohort with up to 10 years of follow-up. METHODS: We conducted a retrospective longitudinal cohort study using data from the Sant Pau Initiative on Neurodegeneration, a research project performed at the Sant Pau Memory Unit between 2011 and 2022. Participants were classified into clinical stages 1-6 based on AD pathology status in CSF, determined by the p-tau181/Aβ1-42 ratio. The primary outcomes were cognitive decline, measured by changes in the Mini-Mental State Examination (MMSE), and progression to dementia. Plasma p-tau217 and CSF p-tau181 levels were assessed, and statistical analysis was performed using linear mixed-effects models for longitudinal changes in MMSE scores and Cox proportional hazard regression was used to examine progression to dementia. RESULTS: A total of 731 participants (mean age 71.5 ± 10.1 years; 60% female) were included. Plasma p-tau217 levels showed a significant increase across advancing AD stages, with all between-group comparisons remaining significant after false discovery rate adjustment (p < 0.05). Longitudinal analysis showed a significant increase in plasma p-tau217 (β = 7.7, 95% CI 3.0-12.5, p = 0.002) and CSF p-tau181 (β = 3.2, 95% CI 1.4-5.0, p = 0.001). Baseline plasma p-tau217 levels were associated with faster MMSE decline (β = -0.08, 95% CI -0.11 to -0.05, p < 0.001) and progression to dementia (hazard ratio 1.03, 95% CI 1.01-1.05, p < 0.001), independent of clinical stage. DISCUSSION: Plasma p-tau217 was significantly associated with cognitive and functional decline in AD. These findings support the potential use of plasma p-tau217 as a prognostic marker for monitoring AD progression in clinical practice. Future studies should validate these results across diverse cohorts and explore their utility in early-stage detection and monitoring.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Selma-Gonzalez J, Rubio-Guerra S, García-Castro J, et al. Association of Plasma Phosphorylated Tau 217 With Clinical Deterioration Across Alzheimer Disease Stages. Neurology. 2025. PMID: 40472304. doi:10.1212/WNL.0000000000213769

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。